Laryngeal Cancer Therapeutics Market Report 2026

The laryngeal cancer therapeutics market size has grown strongly in recent years. It will grow from $3.24 billion in 2025 to $3.42 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to high prevalence of tobacco and alcohol consumption, rising incidence of head and neck cancers, increased use of chemotherapy and radiation therapy, expansion of oncology treatment centers, improved cancer diagnosis rates.

The laryngeal cancer therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.42 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to growing adoption of immunotherapy drugs, advancements in targeted therapy development, increasing healthcare expenditure on oncology, rising awareness of early cancer screening, expansion of specialty cancer treatment centers. Major trends in the forecast period include rising adoption of immunotherapy in laryngeal cancer, shift toward organ-preserving treatment approaches, growing use of combination therapy regimens, increasing focus on early-stage cancer management, expansion of personalized treatment planning.

The rising prevalence of tobacco use is expected to drive the growth of the laryngeal cancer therapeutics market in the coming years. Tobacco consists of the leaves of plants from the genus Nicotiana, which are harvested and processed for various purposes, including smoking, chewing, and snuffing. Tobacco consumption is a major risk factor for laryngeal cancer and significantly influences the disease's development and treatment outcomes. Laryngeal cancer therapeutics focus on addressing the effects of tobacco use on the condition and its management. For example, in October 2024, the 2024 National Youth Tobacco Survey published by the US Food and Drug Administration (USFDA), a US federal agency, reported that 1.1% of all students (around 2.25 million) currently used tobacco products, with 10.1% of high school students (approximately 1.58 million) and 5.4% of middle school students (about 640,000) using tobacco. Additionally, 2.8% of students (around 760,000) reported current use of any combustible tobacco product, while 3% (approximately 840,000) reported using multiple tobacco products. Consequently, the growing prevalence of tobacco is contributing to the expansion of the laryngeal cancer therapeutics market.

Major companies operating in the laryngeal cancer therapeutics market are emphasizing the development of innovative products such as perioperative checkpoint inhibitor therapies to enhance patient survival and lower recurrence rates. Perioperative checkpoint inhibitor therapies are treatments administered around the time of surgery (before and/or after) that utilize immune checkpoint inhibitors to strengthen the immune system’s capacity to target cancer cells, aiding in tumor reduction, preventing recurrence, and improving overall survival. For example, in June 2025, Merck & Co. Inc., a US-based pharmaceutical company, obtained US Food and Drug Administration (FDA) approval for Keytruda (pembrolizumab) as a neoadjuvant and adjuvant therapy for resectable locally advanced head and neck squamous cell carcinoma (HNSCC) with PD-L1 expression (CPS ≥1). Keytruda is given before surgery (neoadjuvant) and continued after surgery (adjuvant) alongside radiotherapy, with or without cisplatin, to lower the risk of recurrence and improve progression-free survival. By leveraging the patient’s immune system to eliminate residual cancer cells while integrating with existing surgical and radiation protocols, this advancement enables more precise, patient-specific care, improves treatment outcomes, and signifies a move toward combination immunotherapy strategies in managing laryngeal and other head and neck cancers.

In May 2024, Moffitt Cancer Center, a US-based cancer treatment and research institution, announced a collaboration with Fulgent Pharma. The collaboration aims to enhance cancer treatment through clinical development and pre-clinical co-development initiatives, integrating Moffitt's clinical expertise with Fulgent's nanotherapeutics and genomics platforms to accelerate personalized cancer therapies. Fulgent Pharma is a US-based innovative cancer therapeutics company focused on nanoencapsulation technology and personalized oncology treatments.

Major companies operating in the laryngeal cancer therapeutics market are Pfizer Inc., F. Hoffmann La Roche Ltd., Merck & Co., AbbVie Inc., Novartis AG, Bayer AG, Sanofi-Aventis LLC, Bristol Myers Squibb, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., C.H. Boehringer Sohn AG & Co. KG., Regeneron Pharmaceuticals Inc., Incyte Corporation, Aurobindo Pharma Ltd., Cipla Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Lupin Limited, Seagen Inc., Exelixis Pharmaceuticals Inc., BeiGene Ltd., Taiho Pharmaceutical Co. Ltd., Genentech Inc., Mirati Therapeutics Inc.

North America was the largest region in the laryngeal cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the laryngeal cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the laryngeal cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the laryngeal cancer therapeutics market by increasing the cost of imported oncology drugs, biologics, and specialized manufacturing inputs. Immunotherapy and targeted therapy segments are most affected, particularly in north america and europe due to dependence on cross-border pharmaceutical supply chains. Higher procurement costs have placed pressure on hospital pharmacies and specialty centers. However, tariffs have encouraged local drug manufacturing, regional clinical trials, and long-term strengthening of domestic oncology drug supply capabilities.

The laryngeal cancer therapeutics market research report is one of a series of new reports that provides laryngeal cancer therapeutics market statistics, including laryngeal cancer therapeutics industry global market size, regional shares, competitors with a laryngeal cancer therapeutics market share, detailed laryngeal cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the laryngeal cancer therapeutics industry. This laryngeal cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Laryngeal cancer therapeutics involves the various treatments and therapeutic strategies used to manage laryngeal cancer, a type of cancer that develops in the tissues of the larynx (voice box). The selection of treatment depends on factors such as the stage and location of the cancer, overall health, and personal preferences.

The primary treatment types for laryngeal cancer therapeutics include chemotherapy, immunotherapy, and others. Chemotherapy is a medical treatment that uses potent drugs to destroy or inhibit the growth of rapidly dividing cells, including cancer cells. In laryngeal cancer, chemotherapy is employed to reduce the size of cancerous cells before surgical intervention. The routes of administration include oral and parenteral. These drugs are distributed through hospital pharmacies, online pharmacies, and retail pharmacies to end users such as hospitals, homecare providers, specialty centers, and others.

The laryngeal cancer therapeutics market consists of revenues earned by entities by providing services such as diagnostic services, treatment planning and coordination, surgical interventions, radiation therapy, and chemotherapy administration. The market value includes the value of related goods sold by the service provider or included within the service offering. The laryngeal cancer therapeutics market includes sales of radiation therapy machines, targeted therapies, immunotherapy drugs, surgical instruments, and voice prostheses. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.